In line with these results, high pAKT levels have been linked to better response to neoadjuvant chemotherapy in breast cancer patients [54], and low pERK expression has been correlated with longer survival of NSCLC patients receiving neoadjuvant chemotherapy [55]. The gene discussed is EIF2AK3; the disease is breast cancer.